Ibrexafungerp
Triterpenoid Antifungal — ANTIINFECTIVES FOR SYSTEMIC USE
Also known as: brexafemme, ibrexafungerp citrate, MK-3118, SCY-078
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Ibrexafungerp is an onp drug in the Triterpenoid Antifungal class catalogued in DrugCentral. It was first approved by the FDA in 2021. Its mechanism of action is classified as Glucan Synthase Inhibitors. DrugCentral lists 3 molecular targets, including FKS, GSC1 and FKS1. Recorded indications include Candidiasis of vagina and Vulvovaginal candidiasis.
- Approval status: onp (first approved 2021 by the FDA).
- Drug class: Triterpenoid Antifungal.
- Mechanism of action: Glucan Synthase Inhibitors.
- Molecular targets: FKS, GSC1 and FKS1 (3 listed in DrugCentral).
- Indications: Candidiasis of vagina and Vulvovaginal candidiasis.
- ATC code: J02AX07 (Other antimycotics for systemic use).
- Molecular formula: C44H67N5O4; molecular weight 730.05 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Candidiasis of vagina
- Vulvovaginal candidiasis
Contraindications (1)
- Pregnancy, function
Mechanism & targets
| Mechanism of action (MoA) | Glucan Synthase Inhibitors |
|---|---|
| Established pharmacologic class | Triterpenoid Antifungal |
Molecular targets (3)
| Target | Gene | Action | Activity |
|---|---|---|---|
| 1,3-Beta-D-glucan-UDP glucosyltransferase | FKS | inhibitor | IC50 8.97 |
| Beta-1,3-glucan synthase catalytic subunit 1 | GSC1 | inhibitor | IC50 8.35 |
| 1,3-Beta-D-glucan-UDP glucosyltransferase | FKS1 | inhibitor | IC50 7.83 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2021-06-01 | FDA | — | SCYNEXIS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
J02AX07 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › Other antimycotics for systemic use |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Ibrexafungerp is on its molecule page.
| Molecular formula | C44H67N5O4 |
|---|---|
| Molecular weight | 730.05 g/mol |
| CAS number | 1207753-03-4 |
| InChIKey | BODYFEUFKHPRCK-ZCZMVWJSSA-N |
| PubChem CID | 46871657 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Ibrexafungerp used for?
DrugCentral lists the following indications for Ibrexafungerp: Candidiasis of vagina and Vulvovaginal candidiasis.
How does Ibrexafungerp work?
Ibrexafungerp is classified as Glucan Synthase Inhibitors; its molecular targets in DrugCentral include FKS (inhibitor), GSC1 (inhibitor) and FKS1 (inhibitor).
When was Ibrexafungerp first approved?
Ibrexafungerp was first approved by the FDA in 2021.
What drug class does Ibrexafungerp belong to?
Ibrexafungerp is in the Triterpenoid Antifungal class.
What is the chemical formula of Ibrexafungerp?
Ibrexafungerp has the molecular formula C44H67N5O4 and a molecular weight of 730.05 g/mol.
Browse: all drugs starting with I · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5462 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4297513 — compound record and bioactivity
- PubChem CID 46871657 — chemical identifiers
- DrugBank DB12471 — drug record
- FDA UNII A92JFM5XNU — substance identity
- DailyMed: FDA labels for Ibrexafungerp — current prescribing information (label search)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.